Onset of Bronchodilation with Fluticasone/Formoterol Combination Versus Fluticasone/Salmeterol in an Open-Label, Randomized Study

• DOI: 10.1007/s12325-012-0058-0
• Publication Date: 2012-10-18T21:13:07Z
• Authors: René Aalbers; Guy Brusselle; Tammy McIver; Birgit Grothe; Anna Bodzenta-Luk...
• Keywords: Fluticasone; Salmeterol; Bronchodilation; Formoterol Fumarate

The inhaled corticosteroid, fluticasone propionate (fluticasone), and the long-acting beta2-agonist, formoterol fumarate (formoterol), have been combined in a single aerosol inhaler (fluticasone/formoterol). In randomized, open-label study, fluticasone/formoterol showed similar efficacy to fluticasone/salmeterol after 12 weeks of treatment. This post-hoc analysis compared onset bronchodilation with two treatments. Adults mild-to-moderate-severe persistent asthma were randomized (100/10 or 250/10 μg twice daily [b.i.d.]) (100/50 250/50 b.i.d.) for weeks. (the first post-dose time point at which forced expiratory volume 1 second [FEV1] was ≥12% greater than pre-dose value), responder rates proportion patients achieving bronchodilation), changes FEV1 assessed days 0 (baseline) 84. Fluticasone/formoterol (n = 101) provided more rapid over 120 min on (hazard ratio [HR] 1.47 [95% CI 1.05–2.05]) 84 (HR 1.77 1.14–2.73]). odds patient within 5 dosing almost four-times higher day (odds [OR] 3.97 1.96–8.03]) 10-times (OR 9.58 2.14–42.90]); approximately twofold both days. overall percentage increase least-squares (LS) mean during 120-min period significantly (LS treatment difference: 4.70% 1.57–7.83]; P 0.003) (2.79% 0.65–4.93]; 0.011). These analyses that faster fluticasone/salmeterol, maintained benefit may facilitate adherence among asthma.